Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of glepaglutide in short bowel syndrome patients from EASE SBS 2/3
2025-520775-81-00Phase 3Authorised
- Sponsor
- Zealand Pharma
- Start
- Nov 2025
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Treatment-emergent adverse events. Planned start Nov 2025; status: authorised.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2025-520775-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520775-81-00.